Novozymes is the world leader in bioinnovation, producing a wide range of industrial enzymes, microorganisms, and biopharmaceutical ingredients.
25. April 2012
Overall sales growth of 2% in DKK for Q1 2012 is in line with expectations, on the back of a challenging comparison in the first quarter of 2011. The outlook for sales growth is maintained at 7–11% in DKK and 4–8% organically.
19. January 2012
Growth in local currencies was 10% (8% DKK, 7% organic) compared to 2010. EBIT increased by 11% and took the EBIT margin to 22.3% despite a negative impact from higher raw material prices, acquisitions, and unfavorable currency rates.
9. May 2012
3. May 2012
| Copyright © 2010 Novozymes. All Rights Reserved.